ImmunityBio, Inc. has announced updated efficacy data from its ongoing QUILT-106 trial evaluating CD19-directed CAR-NK cell therapy combined with rituximab in patients with Waldenström macroglobulinemia, a rare subtype of non-Hodgkin lymphoma. The company disclosed that two patients remain in durable complete remission at 7 and 15 months after receiving a finite outpatient course of the chemotherapy- and lymphodepletion-free immunotherapy.

Why this early signal could reshape thinking around durability, lymphodepletion, and outpatient cell therapy delivery

The topline finding—that complete remission has persisted beyond a year in a patient with 95% bone marrow infiltration, without any additional therapy—is not merely an efficacy milestone for ImmunityBio’s QUILT-106 program. It marks a potential inflection point for the broader cell therapy field, which remains constrained by toxicity management, hospital-based administration, and high costs associated with autologous CAR-T workflows.

What distinguishes QUILT-106 is not only its clinical performance to date, but the therapeutic hypothesis it operationalizes: that natural killer (NK) cells can be used as an off-the-shelf, allogeneic platform with dual functionality—direct cytotoxicity via the engineered CAR, and indirect antibody-mediated cytotoxicity when paired with rituximab. This dual targeting of CD19 and CD20 across four treatment cycles, without lymphodepletion or inpatient monitoring, opens a fresh front in the conversation around feasibility, especially for indolent B-cell malignancies.

Industry observers tracking the outpatient viability of cell therapies have noted that most CAR-T constructs currently require high-dose chemotherapy conditioning regimens, prolonged hospital stays, and carry risk of cytokine release syndrome (CRS) or neurotoxicity. In contrast, QUILT-106’s use of high-affinity CD16 (FcγRIIIa 158V) to enable antibody-dependent cellular cytotoxicity (ADCC) in synergy with rituximab offers a non-myeloablative option with early data showing no serious adverse events in any of the four treated patients.

What differentiates CD19 CAR-NK from other CD19-targeted platforms in the NHL landscape

The CD19-directed space in non-Hodgkin lymphoma has become increasingly crowded, particularly with approved CAR-T therapies such as Gilead Sciences’ Yescarta and Novartis’ Kymriah. However, these autologous platforms have consistently faced manufacturing delays, scalability issues, and safety concerns in patients with frail physiology—issues that are especially problematic in older patients with Waldenström’s macroglobulinemia, where disease is typically indolent but incurable.

ImmunityBio’s approach with CD19 CAR-NK provides three key contrasts. First, it avoids the need for personalized leukapheresis and genetic engineering, offering a cryopreserved off-the-shelf product. Second, it incorporates rituximab into its backbone rather than positioning as a standalone agent, enabling dual-antigen coverage. Third, it removes the requirement for lymphodepleting chemotherapy, which remains a barrier for heavily pretreated patients or those with comorbidities.

If these advantages translate into broader patient-level data with consistent response durability, CD19 CAR-NK could begin to segment the NHL treatment space further—particularly among patients unsuitable for CAR-T, or those who have relapsed after BTK inhibitors and anti-CD20 agents.

What this could enable in terms of next-generation combination regimens and NK-based immunotherapy pipelines

The success of QUILT-106 thus far lays the groundwork for the company’s planned exploration of a triple-combination approach: CD19 CAR-NK + rituximab + ANKTIVA (nogapendekin alfa inbakicept). This IL-15 agonist fusion complex is designed to further activate NK and CD8+ T cells, potentially amplifying immune-mediated cytotoxicity and memory response.

This is a meaningful move because it could position ImmunityBio to compete not only within the NK cell therapy niche—alongside players like Fate Therapeutics, Artiva Biotherapeutics, and Nkarta—but also in broader checkpoint-inhibitor or cytokine-enhanced combinations where tumor microenvironment suppression remains a hurdle.

Clinicians watching this space will be interested in how well ANKTIVA can drive expansion and persistence of NK cells in vivo when paired with an engineered CAR platform, and whether memory T-cell reactivation will confer added depth or durability of response. These mechanistic questions remain unanswered but are likely to shape next-stage protocol design and FDA regulatory engagement.

What risks remain around generalizability, scalability, and late-emerging safety signals

Despite the promising update, several caveats remain. The current dataset is based on only four patients, with two evaluable for long-term follow-up. While all patients have remained in clinical disease control thus far, this represents a small and likely highly selected population.

Regulatory watchers suggest that key trial design limitations—such as lack of comparator arms, unblinded evaluation, and limited follow-up duration—will need to be addressed before any discussion of registrational intent. Moreover, while the absence of serious adverse events is encouraging, longer-term surveillance will be required to rule out delayed hematologic toxicity or immune exhaustion.

Manufacturing scalability also remains an open question. While off-the-shelf availability offers theoretical advantages, allogeneic platforms must balance immunogenicity and persistence. Industry analysts will want to understand whether repeat dosing is viable across broader patient cohorts, and how the company plans to scale GMP-compliant production of its t-haNK (targeted, high-affinity NK) platform.

Why outpatient CAR-NK delivery could matter more in low-resource or older populations

If further validated, one of the most significant implications of this therapy will be its outpatient setting of administration. With no need for ICU-grade monitoring or cytotoxic conditioning, CD19 CAR-NK could prove particularly suitable for lower-resource health systems or community oncology centers without specialized cell therapy infrastructure.

Given that Waldenström’s patients are often older and more comorbid, the absence of lymphodepletion also reduces treatment-associated risks that have historically excluded many patients from CAR-T trials. This repositions NK cell therapy as a potentially safer, more flexible immune modality—and one whose convenience profile could be decisive for both payers and patients.

The broader implication is that outpatient delivery models could fundamentally shift reimbursement dynamics for cellular immunotherapies, particularly if health economics analyses show lower total cost of care compared to autologous constructs.

What’s next for QUILT-106 and the Waldenström treatment algorithm

As ImmunityBio continues enrollment in QUILT-106, the durability of response across a broader cohort will be key to understanding whether this therapy can earn its place in treatment algorithms. Currently, options post-BTK inhibitor failure are limited, and patients often rotate between anti-CD20 regimens and alkylating agents with diminishing returns.

If CD19 CAR-NK proves capable of inducing remissions after two cycles and sustaining them beyond a year without retreatment, it may challenge the paradigm of continuous therapy in this indication. Whether this response pattern generalizes beyond indolent lymphoma into more aggressive liquid tumors remains to be seen.

Early signs suggest that the company is positioning the therapy as a platform, not a one-off—especially with the mention of ANKTIVA and potential applications beyond Waldenström’s macroglobulinemia. As the pipeline matures, investors, regulators, and hematologists alike will watch whether ImmunityBio’s strategy can shift the CAR conversation beyond T cells and toward a broader class of immune effectors.

  ANKTIVA, CAR-T alternatives, CD19 CAR-NK, IL-15, ImmunityBio, NK cell therapy, QUILT-106, rituximab, Waldenström lymphoma